Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance

Reuters03-10

Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance

Tonix said it had about USD 208 million in cash as of Dec. 31, 2025, and reported no debt. The company said it expects its cash runway to extend into Q1 2027. Tonix reported USD 1.4 million in net sales for TONMYA over the period from Nov. 17 to Dec. 31, 2025. Tonix said TONMYA wholesale acquisition cost prices are USD 1,860 for a 60-count prescription and USD 930 for a 30-count prescription. The presentation also references Tonix’s marketed migraine products TOSYMRA and ZEMBRACE SymTouch, and includes links to their prescribing information: Patient Information and Patient Information.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618673459?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 01:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618673459","market":"us","top_or_hot":-1,"title":"Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tonix said it had about USD 208 million in cash as of Dec. 31, 2025, and reported no debt. The company said it expects its cash runway to extend into Q1 2027. Tonix reported USD 1.4 million in net sales for TONMYA over the period from Nov. 17 to Dec. 31, 2025. Tonix said TONMYA wholesale acquisition cost prices are USD 1,860 for a 60-count prescription and USD 930 for a 30-count prescription. The presentation also references Tonix’s marketed migraine products TOSYMRA and ZEMBRACE SymTouch, and includes links to their prescribing information: Patient Information and Patient Information.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 01:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tonix said it had about USD 208 million in cash as of Dec. 31, 2025, and reported no debt. The company said it expects its cash runway to extend into Q1 2027. Tonix reported USD 1.4 million in net sales for TONMYA over the period from Nov. 17 to Dec. 31, 2025. Tonix said TONMYA wholesale acquisition cost prices are USD 1,860 for a 60-count prescription and USD 930 for a 30-count prescription. The presentation also references Tonix’s marketed migraine products TOSYMRA and ZEMBRACE SymTouch, and includes links to their prescribing information: Patient Information and Patient Information.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNXP","symbol_name":"Tonix Pharmaceuticals Holding Co","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLShJ5X:1","article_id":"2618673459","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618673459","pubTimestamp":1773075843,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance. Tonix said it had about USD 208 million in cash as of Dec. 31, 2025, and reported no debt. The company said it expects its cash runway to extend into Q1 2027. Tonix reported USD 1.4 million in net sales for TONMYA over the period from Nov. 17 to Dec. 31, 2025. Tonix said TONMYA wholesale acquisition cost prices are USD 1,860 for a 60-count prescription and USD 930 for a 30-count prescription. The presentation also references Tonix’s marketed migraine products TOSYMRA and ZEMBRACE SymTouch, and includes links to their prescribing information: Patient Information and Patient Information.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNXP":"Tonix Pharmaceuticals Holding Co","BK4583":"猴痘概念","BK4139":"生物科技"},"translate_title":"Tonix Pharmaceuticals Holding Corp.发布有关TONMYA纤维肌痛上市和2.08亿美元现金余额的投资者介绍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNXP":0.9},"content_text":"Tonix Pharmaceuticals Holding Corp. Publishes Investor Presentation on TONMYA Fibromyalgia Launch and USD 208 million Cash Balance\n    \n\n        Tonix said it had about USD 208 million in cash as of Dec. 31, 2025, and reported no debt. The company said it expects its cash runway to extend into Q1 2027. Tonix reported USD 1.4 million in net sales for TONMYA over the period from Nov. 17 to Dec. 31, 2025. Tonix said TONMYA wholesale acquisition cost prices are USD 1,860 for a 60-count prescription and USD 930 for a 30-count prescription. The presentation also references Tonix’s marketed migraine products TOSYMRA and ZEMBRACE SymTouch, and includes links to their prescribing information: Patient Information and Patient Information.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618673459","isCrawlerRequest":true}